Science and Enterprise

Tag: USPTO

  • Regulatory Agency Funding Increases in Federal Budgets

    A new report from researchers at Washington University in St. Louis, Missouri and George Washington University in Washington, DC describe increases in funding and staff at federal regulatory agencies over the two most recent fiscal years. Fiscal Stalemate Reflected in Regulators Budget: An Analysis of the U.S. Budget for Fiscal Years 2011 and 2012, by…

  • University Patents Chemical Measurement Device and Process

    Baylor University in Waco, Texas has received a U.S. patent for a new type of polarimeter, an instrument to measure and interpret transverse waves, such as light waves. The new polarimeter was developed by Baylor chemistry professor Kenneth Busch and lab coordinator Dennis Rabbe. United States Patent 7911608 covers not only the device hardware, but…

  • Patent Allowance Given for Glucose Monitoring Method

    Symphony tCGM (Echo Therapeutics) Echo Therapeutics Inc. in Franklin, Massachusetts says it received a notice of allowance from the U.S. Patent Office on the methods for using its continuous non-invasive glucose monitoring system. A notice of allowance indicates that the patent application has not been successfully contested and the company may proceed with registering the…

  • Patent Awarded for Protein Biomarker Cancer Screening

    Van Andel Research Institute (VARI), a biomedical research institute in Grand Rapids, Michigan, and Gentel Biosciences, a biotechnology company in Madison, Wisconsin received a patent for their process to  profile changes in proteins binding to antibodies in test arrays. This process can screen for biomarkers indicating early stages of cancer, including liver and pancreatic cancers…

  • Tufts University Gets Patent for Kidney Disease Treatment

    Researchers at Tufts University’s veterinary school in Grafton, Massachusetts have received a U.S. patent for an antibody-based treatment for hemolytic uremic syndrome (HUS), a potentially fatal outcome of E. coli poisoning and a leading cause of kidney failure in children. The Tufts technology covered by the patent, developed by microbiology professor Saul Tzipori, uses human…

  • U.S. Patent Issued for Gastrointestinal Therapy

    Synergy Pharmaceuticals Inc. in New York says today the U.S. Patent and Trademark Office awarded a patent to the company for its drug candidate SP-333 to treat various gastrointestinal disorders. U.S. Patent No. 7,879,802 was issued on 1 February, according to the company. The patent claims the composition of SP-333 and use in the treatment…

  • USPTO Updates Patent Examiner Guidelines

    The U.S. Patent and Trademark Office (USPTO) has proposed a supplement to its patent examiner guidelines that the agency says will clarify the scope of patent rights to the public. USPTO released the proposed guidelines in the Federal Register for a 60-day public comment period. The new guidelines address section 112 of the Patent Act,…

  • U.S., Europe Agree on Patent Classification Principles

    The U.S. and European patent authorities have agreed on the principles for a new system of classifying patents in their respective jurisdictions. A common classification system is expected to make it easier to search for patents across national boundaries. The United States Patent Trademark Office (USPTO) and European Patent Office (EPO) agreed that the new…

  • USPTO Gives Details of New Expedited Review Process

    The U.S. Patent and Trademark Office (USPTO) released more details of its program that lets patent applicants choose the speed at which their application is processed.  The program consists of three tracks, with higher fees charged for faster patent processing. USPTO plans to publish tomorrow (4 February) in the Federal Register a notice of the…

  • Patent Granted for Lung Disorder Treatment

    Discovery Laboratories Inc., a biotechnology company in Warrington, Pennsylvania, said today the company received a U.S. patent for its treatment of pulmonary inflammation. The patent — number 7,863,241 — expires in 2023. Discovery Labs says the patent covers its KL4 peptide (also known as sinapultide), an engineered pulmonary surfactant that lowers surface tension and promote…